Gujarat Kidney IPO: High Valuation, Low GMP – Should You Invest?

• Gujarat Kidney & Super Speciality IPO opened, closing December 24, with a price band of ₹108-₹114 per share.
• The ₹250.80 crore fresh issue will fund acquisitions (Parekhs Hospital, Ashwini Medical Centre) and a new Vadodara hospital.
• Anchor investors committed over ₹100 crore, but Grey Market Premium (GMP) is low at ₹3, suggesting a modest listing.
• Brokerage Swastika Investmart advises caution due to a high P/E valuation (61x) compared to peers and expansion risks.
• Retail subscription was good on day one, while QIB remained sluggish, indicating mixed investor sentiment.

Why It Matters: Gujarat Kidney IPO offers expansion potential but faces high valuation and modest GMP, urging caution.